Glu-Plasminogen Dosing for Plasminogen Activity Maintenance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel strategies to treat plasminogen-deficiency, as current therapies are lacking for plasminogen-deficient subjects, and there is no effective supplementation therapy available.
Innovation Solution
Administering Glu-plasminogen intravenously at specific dosages (0.5 mg/kg daily, 1.5 mg/kg every two days, 6 mg/kg twice a week, or 45 mg/kg weekly) to increase plasminogen activity levels in plasminogen-deficient subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If plasminogen supplementation therapy is provided to plasminogen-deficient subjects, then plasminogen activity levels are increased, but no effective supplementation therapy has been available until now
Solution Approach 1:
The patent applies parameter changes by establishing specific dosage regimens (0.5 mg/kg daily, 1.5 mg/kg every two days, 6 mg/kg twice weekly, or 45 mg/kg weekly) to optimize plasminogen activity levels. This resolves the contradiction by providing concrete dosing parameters that make supplementation therapy effective and reliable for the first time.
2Quantity of substance
If high dosage LYS-plasminogen is administered, then plasminogen activity increases, but the therapy is non-invasive and no supplementation therapy is currently offered
Solution Approach 1:
The patent implements periodic action through multiple dosing schedules (daily, every-two-days, twice-a-week, and weekly regimens) that maintain plasminogen activity within therapeutic ranges. This resolves the contradiction by providing structured periodic administration protocols that make the non-invasive supplementation therapy practical and implementable.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Subjects of the invention are a method of plasminogen supplementation in a plasminogen-deficient subject, and method for the treatment of plasminogen-deficiency in a plasminogen-deficient subject. These methods comprise administering to the plasminogen-deficient subject a dose of plasminogen, and more particularly Glu-plasminogen, for increasing the subject plasminogen activity level by at least about 1 %, and more particularly by at least about 10%, of the normal plasminogen activity and for maintaining said increased plasminogen activity level over a supplementation period or a treatment period. The plasminogen-deficient subject of the present invention may suffer from Type-I, Type-ll plasminogen-deficiency or an acquired deficiency.